Allogeneic peripheral blood stem cell transplantation using reduced intensity versus myeloablative conditioning regimens for the treatment of leukemia

Stem Cells and Development

Volumn 13, Issue 5, 2004, Pages 571-578

  Vela Ojeda, J ^a,c   Garcia Ruiz Esparza M A ^a   Tripp Villanueva, F ^a   Ayala Sanchez M ^a   Delgado Lamas, J L ^b   Garces Ruiz O ^b   Rubio Jurado, B ^b   Montiel Cervantes, L ^a   Sanchez Cortes E ^a   Garcia Chavez J ^a   Xolotl Castillo, M ^a   Rosas Cabral, A ^a   Salazar Exaire, D ^a   Galindo Rodriguez G ^a   Avina Zubieta A ^a  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c NONE   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN; BUSULFAN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ONDANSETRON; PREDNISOLONE; PREDNISONE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYSTITIS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REGIMEN; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER VEIN OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BLOOD TRANSFUSION; CELL TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MUCOUS MEMBRANE; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RISK; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

CYTOMEGALOVIRUS;

EID: 8144224442     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.2004.13.571     Document Type: Article

References (28)

1. Armitage JO. (1994). Bone marrow transplantation. N Engl J Med 330:827-838.
2. Ringden O, MM Horowitz and RP Gale. (1993). Outcome after allogeneic bone marrow transplant for leukemia in older adults. J Am Med Assoc 270:57-60.
3. Gale RP and RE Champlin. (1984). How does bone marrow transplantation cure leukemia? Lancet 2:28-30.
4. Kolb HJ, A Schattenberg and JM Goldman. (1995). Graft-versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041-2050.
5. Gratwohl A, H Baldomero and J Passweg. (2002). Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey. Bone Marrow Transplant 30:813-831.
6. De La Camara R, A Alonso and JL Steegmann. (2002). Allogeneic hematopoietic stem cell transplantation in patients 50 years of age and older. Haematologica 87:965-872.
7. Weissinger F, BM Sandmaler and DG Maloney. (2001). Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 98:3584-3588.
8. Parker JE, T Shafi and A Pagliuca. (2002). Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 119:144-154.
9. Przepiorka D, D Weisdorf and P Martin. (1995). 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825-828.
10. Sullivan KM, E Agura and C Anasetti. (1991). Chronic graft-versus host disease, other late complications of bone marrow transplantation. Semin Hematol 28:250-259.
11. Bryant E and PJ Martin. (1999). Documentation of engraftment and characterization of chimerism following hematopoietic cell transplantation. In: Hematopoietic Cell Transplantation, 2nd ed. ED Thomas, KG Blume and SJ Forman, eds. Blackwell Science, Boston, pp. 197-206.
12. Slavin S, A Nagler and E Naparstek. (1998). Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763.
13. Giralt S, E Estey and M Albitar. (1997). Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft versus leukemia without myeloablative therapy. Blood 89:4531-4536.
14. Storb R, C Yu and JL Wagner. (1997). Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89:3048-3054.
15. Couriel D, S Giralt and M De Lima. (2000). Graft versus host disease after non-myeloablative versus myeloablative conditioning regimens in fully matched sibling donors hematopoietic stem cell transplants. Blood 96 (Suppl. 1):408a (abstract 1758).
16. Niederwieser D, M Maris and JA Shizuru. (2003). Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101:1620-1629.
17. Corradini P, C Tarella and A Olivieri. (2002). Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 99:75-82.
18. Kobbe G, P Schneider and M Aivado. (2002). Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning. Exp Hematol 30:1346-1353.
19. Garban F, M Attal and JF Rossi. (2001). Immunotherapy by non-myeloablative allogeneic stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation. Leukemia 15:642-646.
20. Mohty M, W Jacot and C Faucher. (2003). Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 17:2168-2177.
21. McSweeney PA, D Niederwieser and JA Shizuru. (2001). Hematopoietic cell transplantation in older patients with hematologic malignancies; replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390-3400.
22. Anagnostopoulos A and S Giralt. (2002). Critical review on non-myeloablative stem cell transplantation (NST). Crit Rev Oncol Hematol 44:175-190.
23. Antin JH. (2003). Stem cell transplantation-harnessing of graft-versus-malignancy. Curr Opin Hematol 10:440-444.
24. González M, R López-Pérez and R García-Sanz. (2001). Debate round table: comments concerning chimerism studies. Leukemia 15:186-188.
25. Bacigalupo A. (2002). Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT). Bone Marrow Transplant 29:191-195.
26. Feinstein L and R Storb. (2001). Nonmyeloablative hematopoietic cell transplantation. Curr Opin Oncol 13:95-100.
27. Ruiz-Argüelles GJ, D Gómez-Almaguer and B López-Martínez. (2002). Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 87:854-855.
28. Michallet M, K Bilger and F Garban. (2001). Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol 19:3340-3349.